$LQDA

Bloch Stephen M sold $14.3M of LQDA (indirect holdings)

Bloch Stephen M sold 220,835 indirectly-held shares of Liquidia Corp (LQDA) at an average of $64.64 ($64.27–$66.19, $14.27M total) across 5 trades over 2026-06-08 to 2026-06-09.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosure provides incremental sentiment information (insider reducing holdings) but lacks any accompanying fundamental update.

02

Market read

Traders may monitor for follow-on insider activity or whether the sale coincides with other company-specific catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The filing shows indirect ownership and multiple trades; without stated rationale, traders may overinterpret the signal versus broader price/volume trends.

Relevance 7/10Novelty 5/10Timing: Filed 2026-06-10; transactions dated 2026-06-08 to 2026-06-09.

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.27M of LQDA shares via open-market transactions (Form 4), reducing insider exposure.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The article is a primary-source insider transaction (Form 4) with sizable dollar value, but it does not include earnings, guidance, clinical, regulatory, or deal information that would reprice the business.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect negative company outlook, especially without a disclosed 10b5-1 plan context.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Stephen M. Bloch

    Director who sold 220,835 shares of LQDA for ~$14.27M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient